| dbo:abstract |
Muraglitazar (proposed tradename Pargluva) is a dual peroxisome proliferator-activated receptor agonist with affinity to PPARα and PPARγ. The drug had completed phase III clinical trials, however in May, 2006 Bristol-Myers Squibb announced that it had discontinued further development. Data on muraglitazar is relatively sparse due to the recent introduction of this agent. One double-blind randomized clinical trial comparing muraglitazar and pioglitazone found that the effects of the former were favourable in terms of HDL-C increase, decrease in total cholesterol, apolipoprotein B, triglycerides and a greater reduction in HbA1c (p <0.0001 for all comparisons). However, the muraglitazar group had a higher all-cause mortality, greater incidence of edema and heart failure and more weight gain compared to the pioglitazone group. A meta-analysis of the phase II and III clinical trials of muraglitazar revealed that it was associated with a greater incidence of myocardial infarction, stroke, transient ischemic attacks and congestive heart failure (CHF) when compared to placebo or pioglitazone. By calling attention to adverse events made public through the FDA advisory committee process, Dr Nissen came upon a mechanism to steer FDA from the outside. This mechanism came to fruition with rosiglitazone (Avandia)and led to FDA requiring demonstration of cardiac safety for new drugs to treat type 2 diabetes. This process is described by Dr Robert Misbin in INSULIN-History from an FDA Insider, published June 1, 2020 on Amazon. (en) |
| dbo:casNumber |
331741-94-7 |
| dbo:chEMBL |
557580 |
| dbo:fdaUniiCode |
W1MKM70WQI |
| dbo:kegg |
D05091 |
| dbo:pubchem |
206044 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Muraglitazar.svg?width=300 |
| dbo:wikiPageID |
16315269 (xsd:integer) |
| dbo:wikiPageLength |
5957 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1021989801 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Meta-analysis dbr:Apolipoprotein_B dbr:PPAR_agonist dbc:Abandoned_drugs dbc:Carbamates dbc:Phenol_ethers dbr:Glycated_hemoglobin dbr:Myocardial_infarction dbr:Stroke dbr:Clinical_trial dbr:P-value dbr:Bristol-Myers_Squibb dbr:Transient_ischemic_attack dbr:Triglyceride dbr:Heart_failure dbr:Edema dbc:Oxazoles dbr:Cholesterol dbc:PPAR_agonists dbr:High-density_lipoprotein dbr:Pioglitazone dbr:Peroxisome_proliferator-activated_receptor_alpha dbr:Peroxisome_proliferator-activated_receptor_gamma |
| dbp:atcPrefix |
None (en) |
| dbp:c |
29 (xsd:integer) |
| dbp:casNumber |
331741 (xsd:integer) |
| dbp:chembl |
557580 (xsd:integer) |
| dbp:chemspiderid |
178524 (xsd:integer) |
| dbp:h |
28 (xsd:integer) |
| dbp:iupacName |
N-[carbonyl]-N-{4-[2-ethoxy]benzyl}glycine (en) |
| dbp:kegg |
D05091 (en) |
| dbp:legalStatus |
Development terminated (en) |
| dbp:n |
2 (xsd:integer) |
| dbp:o |
7 (xsd:integer) |
| dbp:pubchem |
206044 (xsd:integer) |
| dbp:smiles |
CC1=CCCOC3=CC=CCNCOC4=CC=COC (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
IRLWJILLXJGJTD-UHFFFAOYSA-N (en) |
| dbp:synonyms |
2 (xsd:integer) |
| dbp:unii |
W1MKM70WQI (en) |
| dbp:verifiedfields |
changed (en) |
| dbp:verifiedrevid |
407806745 (xsd:integer) |
| dbp:watchedfields |
changed (en) |
| dbp:width |
315 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Gastrointestinal-drug-stub dbt:Drugbox dbt:PPAR_modulators dbt:Reflist dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Ebicite dbt:Fdacite dbt:Keggcite dbt:Stdinchicite dbt:Oral_hypoglycemics |
| dcterms:subject |
dbc:Abandoned_drugs dbc:Carbamates dbc:Phenol_ethers dbc:Oxazoles dbc:PPAR_agonists |
| gold:hypernym |
dbr:Agonist |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatCarbamates yago:Abstraction100002137 yago:Carbamate114792281 yago:Chemical114806838 yago:Compound114818238 yago:Element114840755 yago:Material114580897 yago:Matter100020827 yago:Part113809207 yago:PhysicalEntity100001930 yago:Quintessence114847103 yago:Relation100031921 dbo:Drug yago:Salt115010703 yago:Substance100019613 yago:WikicatPhenolEthers umbel-rc:DrugProduct |
| rdfs:comment |
Muraglitazar (proposed tradename Pargluva) is a dual peroxisome proliferator-activated receptor agonist with affinity to PPARα and PPARγ. The drug had completed phase III clinical trials, however in May, 2006 Bristol-Myers Squibb announced that it had discontinued further development. (en) |
| rdfs:label |
Muraglitazar (en) |
| owl:sameAs |
freebase:Muraglitazar yago-res:Muraglitazar wikidata:Muraglitazar dbpedia-sh:Muraglitazar dbpedia-sr:Muraglitazar dbpedia-vi:Muraglitazar https://global.dbpedia.org/id/4rXUP |
| prov:wasDerivedFrom |
wikipedia-en:Muraglitazar?oldid=1021989801&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Muraglitazar.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:Muraglitazar |
| is dbo:wikiPageRedirects of |
dbr:Pargluva dbr:Muroglitazar |
| is dbo:wikiPageWikiLink of |
dbr:PPAR_agonist dbr:Pargluva dbr:List_of_drugs:_Mp–My dbr:Muroglitazar |
| is foaf:primaryTopic of |
wikipedia-en:Muraglitazar |
